CannTrust (TSX:TRST) Scandal Hurts the Marijuana Industry

The scandal at CannTrust Holdings Inc. (TSX:TRST)(NYSE:CTST) brought dishonour to the marijuana industry. Investor confidence has eroded, and the stock is sinking fast.

Businessman looking at a red arrow crashing through the floor

Image source: Getty Images.

The shares of CannTrust Holdings (TSX:TRST)(NYSE:CTST) are down 60.73% year to date. It’s hard to imagine the stock of a major cannabis player falling by this much when the sector’s organic growth is underway. CannTrust’s admission of wrongdoing this month is the latest disgrace to hit the cannabis space.

The scandal could hurt the marijuana industry. The cannabis producers are supposed to squeeze the black market. But CannTrust did the opposite and sold unlicensed cannabis. CannTrust has placed the marijuana industry in a tough spot. New legislative measures might be introduced and more regulatory probes conducted.

Shocking discovery

Health Canada, the regulatory agency in charge of the marijuana industry, discovered the unsound activities following a random inspection in June.

Five cultivation rooms in CannTrust’s flagship Niagara greenhouse was cultivating and selling unlicensed cannabis between October 18 and March 19. These cultivation rooms only obtained the proper licences in April.

The deliberate disregard of industry regulations forced Health Canada to place on hold the harvested 5,200 kilos of dried cannabis at the Niagara facility. Meanwhile, CannTrust voluntarily put on hold the equivalent of 7,500 kilos of cannabis production from the company’s other facility in Vaughan. All shipments and sales were stopped, too.

According to Health Canada, the suspension is indefinite until such time the overseeing agency deems that CannTrust has fully complied with cannabis regulations in Canada. Thus, the company is doomed and would be unable to execute and implement business strategies.

Consequences

Canopy Growth’s firing of CEO Bruce Linton due to excessive spending and mounting losses is still fresh in the minds of investors. This scandal will have serious repercussions, and the axe is falling. An independent “Special Committee” was formed by CannTrust’s board of directors to conduct an investigation.

CannTrust’s board terminated CEO Peter Acierto with cause effective immediately, and Chairman Eric Paul relinquished his post after being demanded to resign. Special Committee Chairman Robert Marcovitch was appointed as interim CEO.

What is alarming is that Acierto and Paul knew the illicit activities months before it was discovered. Media reports are alleging that based on the company’s internal e-mails, both of them were informed in November about the unlicensed rooms growing cannabis.

Aside from the senior leadership changes, CannTrust will make additional operational changes. Completing the investigation is the company’s first priority as Health Canada continues with quality product testing. Appropriate actions will be taken after the conclusion of the thorough investigation within the next few days.

Reset and rebuild

Acierto made a fatal error in judgment. He said his team was building a culture of transparency, yet they were skirting Canadian cannabis regulations. Health Canada might decide to impose heavy fines and perform more inspections.

The volume of cannabis production seized by Health Canada is just a small percentage of CannTrust’s potential annual production capacity of 400,000 kilograms. That capacity would have allowed CannTrust to assume the industry-leading position. But the company is caged and needs to reset and rebuild. Another cannabis producer taking over is a possibility.

Cannabis producers should learn a valuable lesson and toe the line. CannTrust just lost the trust and confidence of investors.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in the companies mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »